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Open access under CC BY-NC-ND license.Abstract Methodology was developed to obtain a series of unusual alkoxy- and phenoxyalkyl
ethers of secondary and tertiary ethynylpiperidin-4-ols representative examples of which were
evaluated for analgesic, anti-bacterial, anti-spasmotic, and anti-allergic activity. Twenty-two
new compounds were prepared and identiﬁed by elemental and spectra analyses. Etheriﬁcation
of 4-hydroxypiperidin-4-ols was accomplished via Williamson ether-type syntheses in dry DMF.
Side reactions of the bromides used appeared to involve complex processes with DMF under a
variety of conditions employed which led to modest yields of products. Since all target molecules
were oils at room temperature, conversions to b-cyclodextrins were accomplished and served as
vehicles for pharmacological screening. Several ethynyl-substituted agents displayed deep analge-
sic activity in the ‘‘tail ﬂick’’ model although some alkoxy- and phenoxy ethers from secondary
alcohols were less effective as analgesics (Table 1). Interestingly, LD50 values for the agents
210 V.K. Yu et al.exceeded that of a number of clinical agents including Dimedrole, Klemastine, Lidocaine, No-spa,
Tramal, Streptomycin, and Euphilline. Three representative examples of the agents (Table 2)
exhibited moderate anti-bacterial action against Escherichia coli, Salmonella chloerae suis, Salmo-
nella typhimurium, and Staphylococcus aureus, but did not exceed that of Streptomycin. The
absence of the ethynyl ether group resulted in no anti-bacterial activity in several ethers. A few
agents possessed anti-spasmotic ability, especially the ethers of 1-(2-ethoxyethyl)-4-ethynyl-4-
hydroxypiperidines in various preparations (Table 3), and included the systems of acetylcho-
line-induced spasms, the histamine-induced spasms, and the calcium chloride-induced spasms.
Two examples void of the ethynyl group were not effective as anti-spasmotic compounds. A small
survey of ﬁve agents for anti-allergic properties (Table 4) revealed that two with ethynyl groups
were similar in activity with Dimedrole but less than that of Klemastine in screens using acetyl-
choline and histamine systems. Overall, these families of piperidines possess a wide variety of
important biological properties which require further exploration.
ª 2009 King Saud University.Open access under CC BY-NC-ND license.1. Introduction
The effect of ether linkages on useful biological activity in
piperidine systems has not been fully recognized. Preliminary
investigations revealed that such linkages in certain C-substi-
tuted and N-substituted piperidines conveyed medicinal prop-
erties which exceeded activities of a number of
pharmacologically active pharmaceuticals (Praliyev and Yu,
2005). The major component required for high activity was
the presence of the ether group. Two products from prior work
exhibited a wide range of pharmacological actions and are cur-
rently in use (Praliyev et al., 1994, 1996). The two agents are
the analgesic Prosidol (Praliyev et al., 1994) and the anes-
thetic/anti-arrhythmic Kazcaine (Praliyev et al., 1996).
In the current report, one objective was to alter the basic
piperidine structure by the inclusion of additional ether link-
ages, particularly at C-4, while retaining the N-alkoxyalkyl
group and an alkynyl group at C-4. Only a very few examples
exist in the literature where selected 4-aryloxypiperidines are
described with important biological activity (Puhakka et al.,
1977; Lapa et al., 2005; Weis et al., 2003; Waldmeier et al.,
1986; Patat et al., 1994; Mattson and Catt, 1995; Duggan
et al., 1994).2. Experimental
Both 1H and 13C NMR spectra were recorded on a Varian-
Mercury spectrometer operating at 300 MHz (1H) and
75 MHz (13C), respectively, in DCCl3 as solvent and HMDS
as the internal standard. IR spectra were obtained as ﬁlms
on a Nicolet 5-700 FT-I unit. Elemental analyses were per-
formed on a unit from CE-440 EAI Exeter Analytical, Inc.All chromatography employed weakly acidic alumina (Fluka,
particle size was 0.05–0.15 mm). 1-Methyl-4-piperidin-4-one
(1) (Prostavov and Gaivoronskaya, 1978; Chen and LeFevre,
1965) was purchased (Aldrich) and used directly. Members
of 7 were prepared as described (Korablev et al., 1985).
2.1. General procedures for the preparation of alkoxyalkyl ethers
of N-substituted piperidin-4-ols
To an ice-cooled solution of the required piperidin-4-ol
(1.0 mol) in freshly distilled DMF (20 mmol) was added
KOH (5.0 mol). The appropriate alkoxyalkyl bromide
(1.0 mol) in DMF (15 mmol) was added dropwise at room
temperature with stirring which was continued for 70–100 h.
The product was extracted with hexane and then with benzene
to remove the starting piperidin-4-ol. The organic solutions
were dried (MgSO4) and then were distilled under vacuum to
yield the pure product. All starting materials were distilled.
2.2. General procedures for the preparation of phenoxyalkyl
ethers of N-substituted piperidin-4-ols
To an ice-cooled solution of the required piperidin-4-ol
(1.0 mol) in freshly distilled DMF (20 mmol) was added
KOH (5.0 mol). The appropriate phenoxyalkyl bromide
(1.0 mol) in DMF (15 mmol) was added dropwise at room
temperature with stirring which was continued for 70–100 h.
The remaining procedure was as above for the alkoxyalkyl
ethers with the following exceptions. The ﬁnal dried (MgSO4)
solution was evaporated, and the residual oil was chromato-
graphed over alumina with hexane:dioxane (10:1) except where
noted.
2.2.1. 1-(2-Methoxyethyl)-4-piperidin-4-one (2)
Oil, 17.70 g (45.3%); b.p. 98 C/2 mm; Rf 0.82 (ether:hexane,
2:1); IR: 1720 (C‚O), 1116 (COC) cm1; 13C NMR ppm
41.1 (C-3/C-5), 53.7 (C-2/C-6), 56.8 (NCH2), 58.9 (C-9), 70.4
(C-8), 208.9 (C-4). Anal. Calcd for C8H15NO2: C, 61.12; H,
9.62; N, 8.91. Found: C, 61.28; H, 9.79; N, 8.93.
2.2.2. 1-(2-Ethoxyethyl)-4-piperidin-4-one (3)
Oil, 28.49 g (73.3%), b.p. 84–86 C/2 mm; Rf 0.82 (ether:hex-
ane, 2:1); IR (ﬁlm) 1725 (C‚O), 1120 (COC) cm1; 13C
NMR ppm 14.6 (C-10), 40.7 (C-3/C-5), 53.1 (C-2/C-6), 53.6
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C9H17NO2: C, 63.13; H, 10.01; N, 8.18. Found: C, 63.28; H,
10.31; N, 8.12.
2.2.3. 1-Methylpiperidin-4-ol (4)
Oil, 8.34 g (82.0%); Rf 0.18 (hexane:dioxane, 2:1); IR:
3240 cm1 (OH); 1H NMR d 1.52–1.64 (m, 2H, H-3ax, H-
5ax), 1.82–1.87 (m, 2H, H-3eq, H-5eq), 2.08 (bt, 2H, H-2ax,
H-6ax, J= 10.2 Hz), 2.22 (s, 3H, NCH3), 2.69–2.73 (m, 2H,
H-2eq, H-6eq), 3.59 (m, 1H, H-4);
13C NMR ppm 34.2 (C-3/
C-5), 45.9 (NCH3), 53.4 (C-2/C-6), 66.7 (C-4). Anal. Calcd
for C6H13NO: C, 62.57; H, 11.38; N, 12.16. Found: C, 62.58;
H, 11.38; N, 11.36 (Hennion and O’Shea, 1958).
2.2.4. 1-(2-Methoxyethyl) piperidin-4-ol (5)
Oil, 4.78 g (94.0%); Rf 0.24 (hexane:dioxane, 2:1); IR:
3605 cm1 (OH), 1115 cm1 (COC); 1H NMR d 1.46–1.58
(m, 2H, H-3ax, H-5ax), 1.76–1.81 (m, 2H, H-3eq, H-5eq), 2.08
(ddd, 2H, H-2ax, H-6ax, J= 12.6 Hz, 2.7 Hz), 2.47 (t, 2H,
NCH2), 2.69–2.76 (m, 2H, H-2eq, H-6eq), 3.25 (s, 3H, H-9),
3.42 (t, 2H, H-8), 3.56 (m, 1H, H-4); 13C NMR ppm 34.2 (C-
3/C-5), 51.6 (C-2/C-6), 57.6 (NCH2), 58.8 (C-9), 67.5 (C-4),
70.3 (C-8). Anal. Calcd for C8H17NO2: C, 60.35; H, 10.76;
N, 8.80. Found: C, 60.42; H, 10.79; N, 8.93.
2.2.5. 1-(2-Ethoxyethyl)piperidin-4-ol (6)
Oil, 17.76 g (95.2%); Rf 0.32 (hexane:dioxane, 2:1); IR:
3617 cm1 (OH), 1125 cm1 (COC); 1H NMR d 1.18 (t, 3H,
H-10), 1.54–1.66 (m, 2H, H-3ax, H-5ax), 1.85–1.91 (m, 2H,
H-3eq, H-5eq), 2.21 (ddd, 2H, H-2ax, H-6ax, J= 11.7 Hz,
1.8 Hz), 2.58 (t, 2H, NCH2), 2.80–2.86 (m, 2H, H-2eq, H-
6eq), 3.48 (q, 2H, H-9), 3.55 (t, 2H, H-8), 3.65 (m, 1H, H-4);
13C NMR ppm 15.1 (C-10), 34.0 (C-3/C-5), 51.6 (C-2/C-6),
57.6 (NCH2), 66.4 (C-9), 67.2 (C-4), 68.4 (C-8). Anal. Calcd
for C9H19NO2: C, 62.39; H, 11.05; N, 8.08. Found: C, 62.51;
H, 11.27; N, 7.90.
2.2.6. 1-(2-Ethoxyethyl)-4-ethynyl-piperidin-4-ol (8)
20.17 g (88.3%); m.p. 81–82 C; Rf 0,21 (hexane:dioxane, 2:1);
IR: 3580 (OH), 3300 („CH), 2107 (C„C), 1110 cm1
(COC); 1H NMR d 1.18 (t, 3H, H-10), 1.80-1.97 (m, 4H,
H-3ax, H-5ax, H-3eq, H-5eq), 2.46 (ddd, 2H, H-2ax, H-6ax,
J= 11.4 Hz, 3.0 Hz), 2.50 (s, 1H, „CH), 2.60 (t, 2H,
NCH2), 2.73 (m, 2H, H-2eq, H-6eq), 3.48 (q, 2H, H-9), 3.56
(t, 2H, H-8), 3.71 (bs, H, 4-OH); 13C NMR ppm 14.8 (C-
10), 38.5 (C-3/C-5), 50.1 (C-2/C-6), 57.0 (NCH2), 65.6 (C-4),
66.0 (C-9), 67.9 (C-8), 72.4 („CH), 87.0 („C). Anal. Calcd
for C11H19NO2: C, 66.97; H, 9.71; N, 7.10. Found: C,
67.01; H, 9.58; N, 7.33.
2.2.7. 4-(2-Methoxyethoxy)-1-methylpiperidine (9)
Oil, 0.34 g (22.3%); Rf 0.17 (hexane:dioxane, 2:1); IR:
1112 cm1 (COC); 1H NMR d 1.57–1.69 (m, 2H, H-3ax, H-
5ax), 1.87–1.93 (m, 2H, H-3eq, H-5eq), 2.07 (ddd, 2H, H-2ax,
H-6ax, J= 12.0 Hz, 2.7 Hz), 2.24 (s, 3H, NCH3), 2.68–2.72
(m, 2H, H-2eq, H-6eq), 3.31 (m, 1H, H-4), 3.37 (s, 3H, OCH2-
CH2OCH3), 3.52 (t, 2H, OCH2CH2OCH3), 3.59 (t, 2H, OCH2-
CH2OCH3);
13C NMR ppm 31.3 (C-3/C-5) 46.1 (NCH3), 53.5
(C-2/C-6), 59.0 (OCH2CH2OCH3), 67.1 (OCH2CH2OCH3),
72.2 (OCH2CH2OCH3), 75.2 (C-4). Anal. Calcd for
C9H19NO2: C, 62.39; H, 11.05; N, 8.08. Found: C, 62.44; H,
10.96; N, 8.22.2.2.8. 4-(2-Methoxyethoxy)-1-(2-methoxyethyl)piperidine (10)
Oil, 0.23 g (16.9%); Rf 0.53 (hexane:dioxane, 2:1); IR:
1108 cm1 (COC); 1H NMR d 1.58–1.70 (m, 2H, H-3ax, H-
5ax), 1.86–1.93 (m, 2H, H-3eq, H-5eq), 2.14 (ddd, 2H, H-2ax,
H-6ax, J= 12.2 Hz, 2.4 Hz), 2.54 (t, 2H, NCH2), 2.76–2.83
(m, 2H, H-2eq, H-6eq), 3.30 (m, 1H, H-4), 3.33 (s, 3H, H-9),
3.37 (s, 3H, OCH2CH2OCH3), 3.48 (t, 2H, H-8), 3.52 (t, 2H,
OCH2CH2OCH3), 3.59 (t, 2H, OCH2CH2OCH3);
13C
NMR ppm 31.1 (C-3/C-5), 51.7 (C-2/C-6), 57.8 (NCH2), 58.8
(C-9), 59.0 (OCH2CH2OCH3), 67.0 (OCH2CH2OCH3), 70.4
(C-8), 72.2 (OCH2CH2OCH3), 75.6 (C-4). Anal. Calcd for
C11H23NO3: C, 60.80; H, 10.67; N, 6.45. Found: C, 60.80;
H, 10.66; N, 6.19.
2.2.9. 1-(2-Ethoxyethyl)-4-(2-methoxyethoxy)piperidine (11)
Oil, 0.20 (13.3%); Rf 0.57 (hexane:dioxane, 2:1); IR: 1108 cm
1
(COC); 1H NMR d 1.18 (t, 3H, H-10); 1.57–1.68 (m, 2H, H-
3ax, H-5ax), 1.87–1.92 (m, 2H, H-3eq, H-5eq), 2.15 (ddd, 2H,
H-2ax, H-6ax, J= 12.2 Hz, 2.4 Hz), 2.55 (t, 2H, NCH2),
2.78–2.84 (m, 2H, H-2eq, H-6eq), 3.32 (m, 1H, H-4), 3.37 (s,
3H, OCH2CH2OCH3), 3.48 (q, 2H, H-9), 3.51 (t, 2H, H-8),
3.53 (t, 2H, OCH2CH2OCH3), 3.59 (t, 2H, OCH2CH2OCH3);
13C NMR ppm 15.1 (C-10), 31.1 (C-3/C-5), 51.7 (C-2/C-6),
57.7 (NCH2), 59.0 (OCH2CH2OCH3), 66.4 (C-9), 67.0 (OCH2-
CH2OCH3), 68.3 (C-8), 72.2 (OCH2CH2OCH3), 75.5 (C-4).
Anal. Calcd for C12H25NO3: C, 62.30; H, 10.89; N, 6.05.
Found: C, 62.33; H, 10.86; N, 6.30.
2.2.10. 4-(2-Ethoxyethoxy)-1-methylpiperidine (12)
Oil, 0.28 g (16.9%); Rf 0.27 (hexane:dioxane, 2:1); IR:
1104 cm1 (COC); 1H NMR d 1.19 (t, 3H, OCH2CH2-
OCH2CH3); 1.57–1.68 (m, 2H, H-3ax, H-5ax), 1.86–1.92 (m,
2H, H-3eq, H-5eq), 2.07 (ddd, 2H, H-2ax, H-6ax,
J= 12.0 Hz, 2.1 Hz), 2.24 (s, 3H, NCH3), 2.67–2.72 (m,
2H, H-2eq, H-6eq), 3.31 (m, 1H, H-4), 3.52 (q, 2H, OCH2-
CH2OCH2CH3), 3.56 (t, OCH2CH2OCH2CH3), 3.59 (t, 2H,
OCH2CH2OCH2CH3);
13C NMR ppm 15.1 (OCH2-
CH2OCH2CH3), 31.3 (C-3/C-5), 46.2 (NCH3), 53.5 (C-2/C-
6), 66.6 (OCH2CH2OCH2CH3), 67.2 (OCH2CH2OCH2CH3),
70.1 (OCH2CH2OCH2CH3), 75.2 (C-4). Anal. Calcd for
C10H21NO2: C, 64.13; H, 11.30; N, 7.48. Found: C, 64.20;
N, 11.24; N, 7.59.
2.2.11. 4-(2-Ethoxyethoxy)-1-(2-methoxyethyl)piperidine (13)
Oil, 0.22 g (15.2%); Rf 0.65 (hexane:dioxane, 2:1); IR:
1120 cm1 (COC); 1H NMR d 1.19 (t, 3H, OCH2-
CH2OCH2CH3), 1.57–1.69 (m, 2H, H-3ax, H-5ax), 1.86–1.93
(m, 2H, H-3eq, H-5eq), 2.14 (ddd, 2H, H-2ax, H-6ax,
J= 12.0 Hz, 2.7 Hz), 2.54 (t, 2H, NCH2), 2.77–2.81 (m, 2H,
2eq, H-6eq), 3.31 (m, 1H, H-4), 3.33 (s, 3H, H-9), 3.48 (t, 2H,
H-8), 3.52 (q, 2H, OCH2CH2OCH2CH3), 3.56 (t, 2H, OCH2
CH2OCH2CH3), 3.58 (t, 2H, OCH2CH2OCH2CH3);
13C
NMR ppm 15.2 OCH2CH2OCH2CH3, 31.1(C-3/C-5), 51.7
(C-2/C-6), 57.8 (NCH2), 58.8 (C-9), 66.6 (OCH2-
CH2OCH2CH3), 67.2 (OCH2CH2OCH2CH3), 70.1 (OCH2-
CH2OCH2CH3), 70.5 (C-8), 75.5 (C-4). Anal. Calcd for
C12H25NO3: C, 62.30; H, 10.89; N, 6.05. Found: C, 62.30;
H, 10.87; N, 6.04.
2.2.12. 4-(2-Ethoxyethoxy)-1-(2-ethoxyethyl)piperidine (14)
Oil, 0.78 g (18.4%); Rf 0.68 (hexane:dioxane, 2:1); IR: 1112
cm1 (COC); 1H NMR d 1.18 (t, 3H, H-10), 1.19 (t, 3H,
212 V.K. Yu et al.OCH2CH2OCH2CH3), 1.56–1.68 (m, 2H, H-3ax, H-5ax), 1.86-
1.93 (m, 2H, H-3eq, H-5eq), 2.15 (ddd, 2H, H-2ax, H-6ax,
J= 12.2 Hz, 2.4 Hz), 2.55 (t, 2H, NCH2), 2.77-2.83 (m, 2H,
H-2eq, H-6eq), 3.32 (m, 1H, H-4), 3.48 (q, 2H, H-9), 3.51 (t,
2H, H-8), 3.52 (q, 2H, OCH2CH2OCH2CH3), 3.56 (t, 2H,
OCH2CH2OCH2CH3), 3.58 (t, 2H, OCH2CH2OCH2CH3);
13C NMR ppm 15.2 (C-10 and OCH2CH2OCH2CH3), 31.2
(C-3/C-5), 51.8 (C-2/C-6), 57.8 (NCH2), 66.4 (C-9), 66.6
(OCH2CH2OCH2CH3), 67.1 (OCH2CH2OCH2CH3), 68.4 (C-
8), 70,1 (OCH2CH2OCH2CH3), 75.5 (C-4). Anal. Calcd for
C13H27NO3: C, 63.64; H, 11.09; N, 5.71. Found: C, 63.51;
H, 11.03; N, 5.60.
2.2.13. 4-(3-Phenoxypropoxy)-1-methylpiperidine (15)
Oil, 0.76 g (35.1%); Rf 0.18 (hexane:dioxane, 5:1); IR: 3064
(Ar-H), 1104 (COC), 752, 696 cm1; 1H NMR d 1.54–1.65
(m, 2H, H-3ax, H-5ax), 1.82–1.88 (m, 2H, H-3eq, H-5eq), 2.00
(m, 2H, OCH2CH2CH2OPh), 2.08 (bt, H-2ax, H-6ax,
J= 9.9 Hz), 2.21 (s, 3H, NCH3), 2.63 (bs, 2H, H-2eq, H-6eq),
3.27 (m, 1H, H-4), 3.59 (t, 2H, OCH2CH2CH2OPh), 4.03 (t,
2H, OCH2CH2CH2OPh), 6.86–7.28 (m, 5H, Ar-H);
13C
NMR ppm 29.9 (OCH2CH2CH2OPh), 31.1 (C-3/C-5), 46.1
(NCH3), 53.1 (C-2/C-6), 64.1 (OCH2CH2CH2OPh), 64.6
(OCH2CH2CH2OPh), 74.3 (C-4), 114.4 (Ar-C), 120.5 (Ar-C),
129.4 (Ar-C), 158.9 (ArC-O). Anal. Calcd for C15H23NO2: C,
72.25; H, 9.30; N, 5.62. Found: C, 72.20; H, 9.10; N, 5.59.
2.2.14. 4-(3-Phenoxypropoxy)-1-(2-methoxyethyl)piperidine (16)
Oil, 0.51 g (27.7%); Rf (hexane:dioxane, 5:1); IR: 3040 (Ar-H),
1116 (COC), 756, 696 cm1; 1H NMR d 1.55–1.66 (m, 2H, H-
3ax, H-5ax), 1.82–1.90 (m, 2H, H-3eq, H-5eq), 2.00 (m, 2H,
OCH2CH2CH2OPh), 2.14 (ddd, 2H, H-2ax, H-6ax,
J= 11.4 Hz, 2.4 Hz), 2.50 (t, 2H, NCH2), 2.71–2.75 (m, 2H,
H-2eq, H-6eq), 3.28 (m, 1H, H-4), 3.31 (s, 3H, H-9), 3.45 (t,
2H, H-8), 3.59 (t, 2H, OCH2CH2CH2OPh), 4.03 (t, 2H,
OCH2CH2CH2OPh), 6.86–7.27 (m, 5H, Ar-H);
13C NMR ppm
30.0 (OCH2CH2CH2OPh), 31.1 (C-3/C-5), 51.5 (C-2/C-6), 57.8
(NCH2), 58.8 (C-9), 64.0 (OCH2CH2CH2OPh), 64.7
(OCH2CH2CH2OPh), 70.4 (C-8), 74.9 (C-4), 114.4 (Ar-C),
120.5 (Ar-C), 129.4 (Ar-C), 159.0 (ArC-O). Anal. Calcd for
C17H27NO3: C, 69.59; H, 9.28; N, 4.77. Found: C, 69.36; H,
9.51; N, 5.03.
2.2.15. 4-(2-Phenoxyethoxy)-1-(2-ethoxyethyl)piperidine (17)
Oil, 0.45 g (16.7%); Rf 0.30 (hexane:dioxane, 5:1); IR: 2944
(Ar-H), 1116 (COC), 760, 696 cm1; 1H NMR d 1.18 (t, 3H,
H-10), 1.58–1.70 (m, 2H, H-3ax, H-5ax), 1.87–1.92 (m, 2H,
H-3eq, H-5eq), 2.17 (ddd, H-2ax, H-6ax, J= 12.0 Hz, 2.7 Hz),
2.54 (t, 2H, NCH2), 2.77–2.80 (m, 2H, H-2eq, H-6eq), 3.39
(m, 1H, H-4), 3.46 (q, 2H, H-9), 3.52 (t, 2H, H-8), 3.77 (t,
2H, OCH2CH2OPh), 4.08 (t, 2H, OCH2CH2OPh), 6.88–7.27
(m, 5H, Ar-H); 13C NMR ppm 15.1 (C-10), 31.2 (C-3/C-5),
51.6 (C-2/-C-6), 57.8 (NCH2), 66.2 (C-9), 66.4 (OCH2-
CH2OPh), 67.5 (OCH2CH2OPh), 68.4 (C-8), 75.5 (C-4),
114.6 (Ar-C), 120.7 (Ar-C), 129.3 (Ar-C), 158.8 (ArC-O). Anal.
Calcd for C17H27NO3: C, 69.59; H, 9.27; N, 4.78. Found: C,
69.62; H, 9.58; N, 4.83.2.2.16. 4-(3-Phenoxypropoxy)-1-(2-ethoxyethyl)piperidine (18)
Oil, 0.37 g (12.8%); Rf 0.32 (hexane:dioxane, 5:1); IR: 3040
(Ar-H), 1108 (COC), 752, 696 cm1; 1H NMR d 1.18 (t, 3H,
H-10), 1.53–1.65 (m, 2H, H-3ax, H-5ax), 1.83–1.90 (m, 2H,H-3eq, H-5eq), 2.01 (m, OCH2CH2CH2OPh), 2.16 (ddd, 2H,
H-2ax, H-6ax, J= 11.9 Hz, 2.4 Hz), 2.53 (t, 2H, NCH2),
2.72–2.78 (m, 2H, H-2eq, H-6eq), 3.28 (m, 1H, H-4), 3.47 (q,
2H, H-9), 3.52 (t, 2H, H-8), 3.60 (t, 2H, OCH2CH2CH2OPh),
4.05 (t, 2H, OCH2CH2CH2OPh), 6.86–7.29 (m, 5H, Ar-H);
13C NMR ppm 15.1 (C-10), 30.0 (OCH2CH2CH2OPh), 31.2
(C-3/C-5), 51.7 (C-2/C-6), 57.8 (NCH2), 64.1 (OCH2CH2-
CH2OPh), 64.7 (OCH2CH2CH2OPh), 66.4 (C-9), 68.3 (C-8),
75.5 (C-4), 114.5 (Ar-C), 120.5 (Ar-C), 129.4 (Ar-C), 159.0
(ArC-O). Anal. Calcd for C18H29NO3: C, 70.32; H, 9.51; N,
4.56. Found: C, 70.26; H, 9.50; N, 4.74.
2.2.17. 4-(2-Methoxyethoxy)-4-ethynyl-1-methylpiperidine (19)
Oil, 2.06 g (36.3%); Rf 0.52 (hexane:dioxane, 2:1); IR: 3246
(„CH), 2103 (C„C), 1089 (COC) cm1; 1H NMR d 1.82–
1.99 (m, 4H, H-3ax, H-5ax, H-3eq, H-5eq), 2.27 (s, 3H,
NCH3), 2.35 (ddd, 2H, H-2ax, H-6ax, J= 11.7 Hz, 3.0 Hz),
2.50 (s, 1H, „CH), 2.59 (bs, 2H, H-2eq, H-6eq), 3.38 (s, 3H,
OCH2CH2OCH3), 3.55 (t, 2H, OCH2CH2OCH3), 3.71 (t,
2H, OCH2CH2OCH3);
13C NMR ppm 36.5 (C-3/C-5), 45.9
(NCH3), 52.0 (C-2/C-6), 59.0 (OCH2CH2OCH3), 62.7 (OCH2-
CH2OCH3), 71.4 (C-4), 72.0 (OCH2CH2OCH3), 74.5 („CH),
84.4 (C„). Anal. Calcd for C11H19NO2: C, 66.97; H, 9.71; N,
7.10. Found: C, 67.01; H, 9.70; N, 6.86.2.2.18. 4-(2-Ethoxyethoxy)-4-ethynyl-1-methylpiperidine (20)
Oil, 2.55 g (42.0%); Rf 0.85 (hexane:dioxane, 2:1); IR: 3246
(„CH), 2103 (C„C), 1093 (COC) cm1; 1H NMR d 1.19 (t,
3H, OCH2CH2OCH2CH3), 1.81–1.99 (m, 4H, H-3ax, H-5ax,
H-3eq, H-5eq), 2.26 (s, 3H, NCH3), 2.35 (ddd, 2H, H-2ax,
H-6ax, J= 11.4 Hz, 2.7 Hz), 2.50 (s, 1H, „CH), 2.59 (bs,
2H, H-2eq, H-6eq), 3.54 (q, 2H, OCH2CH2OCH2CH3), 3.59
(t, 2H, OCH2CH2OCH2CH3), 3.71 (t, 2H, OCH2-
CH2OCH2CH3);
13C NMR ppm 15.2 (OCH2CH2OCH2CH3),
36.5 (C-3/C-5), 45.9 (NCH3), 51.9 (C-2/C-6), 62.8 (OCH2-
CH2OCH2CH3), 66.5 (OCH2CH2OCH2CH3), 69.8 (OCH2-
CH2OCH2CH3), 71.3 (C-4), 74.5 („CH), 84.3 (C„). Anal.
Calcd for C12H21NO2: C, 68.21; H, 10.02; N, 6.63. Found:
C, 68.08; H, 10.02; N, 6.87.2.2.19. 4-(2-Methoxyethoxy)-4-ethynyl-1-(2-ethoxyethyl)
piperidine (21)
Oil, 7.58 g (38.3%); Rf 0.61 (hexane:dioxane, 2:1); IR: 3246
(„CH), 2104 (C„C), 1089 (COC) cm1; 1H NMR d 1.14 (t,
3H, H-10), 1.77–1.95 (m, 4H, H-3ax, H-5ax, H-3eq, H-5eq), 2.40
(ddd, 2H, H-2ax, H-6ax, J= 12.0 Hz, 3.2 Hz), 2.45 (s, 1H,
„CH), 2.54 (t, 2H, NCH2), 2.64 (bs, 2H, H-2eq, H-6eq), 3.33
(s, 3H, OCH2CH2OCH3), 3.44 (q, 2H, H-9), 3.49 (t, 2H, H-8),
3.51 (t, 2H, OCH2CH2OCH3), 3.67 (t, 2H, OCH2CH2OCH3);
13C NMR ppm 15.2 (C-10), 36.3 (C-3/C-5), 50.4 (C-2/C-6),
57.7 (NCH2), 59.1 (OCH2CH2OCH3), 62.7 (OCH2CH2OCH3),
66.5 (C-9), 68.4 (C-8), 71.8 (C-4), 72.1 (OCH2CH2OCH3), 74.6
(„CH), 84.4 (C„). Anal. Calcd for C14H25NO3: C, 65.85; H,
9.87; N, 5.49. Found: C, 65.85; H, 9.82; N, 5.64.2.2.20. 4-(2-Ethoxyethoxy)-4-ethynyl-1-(2-ethoxyethyl)
piperidine (22)
Oil, 5.45 g (26.6%); Rf 0.91 (hexane:dioxane, 2:1); IR: 3246
(„CH), 2104 (C„C), 1094 (COC) cm1; 1H NMR d 1.13 (t,
3H, H-10), 1.14 (t, 3H, OCH2CH2 OCH2CH3), 1.77–1.94 (m,
4H, H-3ax, H-5ax, H-3eq, H-5eq), 2.40 (ddd, 2H, H-2ax, H-6ax,
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2.64 (bs, 2H, H-2eq, H-6eq), 3.43 (q, 2H, H-9), 3.48 (q, 2H,
OCH2CH2OCH2CH3), 3.49 (t, 2H, H-8), 3.54 (t, 2H, OCH2-
CH2OCH2CH3), 3.66 (t, 2H, OCH2CH2OCH2CH3);
13C
NMR ppm 15.2 (C-10), 15.3 (OCH2CH2OCH2CH3), 36.3
(C-3/C-5), 50.3 (C-2/C-6), 57.7 (NCH2), 62.8 (OCH2-
CH2OCH2CH3), 66.5 (C-9), 66.7 (OCH2CH2OCH2CH3),
68.4 (C-8), 69.9 (OCH2CH2OCH2CH3), 71.7 (C-4), 74.5
(„CH), 84.4 (C„). Anal. Calcd for C15H27NO3: C, 66.88;
H, 10.10; N, 5.20. Found: C, 66.61; H, 9.94; N, 5.16.
2.2.21. 4-(2-Phenoxyethoxy)-4-ethynyl-1-methylpiperidine (23)
Oil, 1.79 g (13.7%); Rf 0,26 (hexane:dioxane, 5:1); IR: 3288
(„CH) 3063 (Ar-H), 2104 (C„C), 1098 (COC), 755,
692 cm1; 1H NMR d 1.85–2.00 (m, 4H, H-3ax, H-5ax, H-3eq,
H-5eq), 2.25 (s, 3H, NCH3), 2.35 (bt, 2H, H-2ax, H-6ax,
J= 8.4 Hz), 2.51 (s, 1H, „CH), 2.56 (bs, 2H, H-2eq, H-6eq),
3.89 (t, 2H, OCH2CH2OPh), 4.11 (t, 2H, OCH2CH2OPh),
6.88–7.28 (m, 5H, Ar-H); 13C NMR 36.4 (C-3/C-5), 45.9
(NCH3), 51.8 (C-2/C-6), 61.9 (t, OCH2CH2OPh), 67.1 (OCH2-
CH2OPh), 71.3 (C-4), 74.6 („CH), 84.5 (C„), 114.6 (Ar-C),
120.7 (Ar-C), 129.3 (Ar-C), 158.7 (ArC-O). Anal. Calcd for
C16H21NO2: C, 74.10; H, 8.16; N, 5.40. Found: C,74.15; H,
8.15; N, 5.67.
2.2.22. 4-(3-Phenoxypropoxy)-4-ethynyl-1-methylpiperidine (24)
Oil, 0.92 g (18.8%); Rf 0,27 (hexane:dioxane, 5:1); IR: 3292
(„CH), 3063 (Ar-H), 2104 (C„C), 1086 (COC), 754, 692
cm1; 1H NMR d 1.82–1.97 (m, 4H, H-3ax, H-5ax, H-3eq, H-
5eq), 2.03 (m, 2H, OCH2CH2CH2OPh), 2.21 (s, 3H, NCH3),
2.33 (bt, 2H, H-2ax, H-6ax J= 9.6 Hz), 2.42 (s, 1H, „CH),
2.51 (bs, 2H, 2-Heq, 6-Heq), 3.72 (t, 2H, OCH2CH2CH2OPh),
4.04 (t, 2H, OCH2CH2CH2OPh), 6.85–7.28 (m, 5H, Ar-H);
13C NMR ppm 29.8 (OCH2CH2CH2OPh), 36.4 (C-3/C-5),
45.9 (NCH3), 51.8 (C-2/C-6), 59.5 (OCH2CH2CH2OPh), 64.6
(OCH2CH2CH2OPh), 70.9 (C-4), 74.2 („CH), 84.5 (C„),
114.4 (Ar-C), 120.4 (Ar-C), 129.3 (Ar-C), 158.9 (ArC-O). Anal.
Calcd for C17H23NO2: C, 74.69; H, 8.48; N, 5.12. Found: C,
74.71; H, 8.48; N, 5.01.
2.2.23. 4-(2-Phenoxyethoxy)-4-ethynyl-1-(2-ethoxyethyl)piperidine
(25)
Oil, 470 g (19.5%); Rf 0,44 (hexane:dioxane, 5:1); IR: 3286
(„CH) 3063 (Ar-H), 2104 (C„C), 1101 (COC), 755, 692
cm1; 1H NMR d 1.18 (t, 3H, H-10), 1.83–2.00 (m, 4H, H-
3ax, H-5ax, H-3eq, H-5eq), 2.44 (ddd, 2H, H-2ax, H-6ax,
J= 11.1 Hz, 3.0 Hz), 2.51 (s, 1H, „CH), 2.57 (t, 2H,
NCH2), 2.66 (bs, 2H, H-2eq, H-6eq), 3.47 (q, 2H, H-9), 3.52
(t, 2H, H-8), 3.89 (t, 2H, OCH2CH2OPh), 4.11 (t, 2H, OCH2-
CH2OPh), 6.88-7.28 (m, 5H, Ar-H);
13C NMR ppm 15.1 (C-
10), 36.2 (C-3/C-5), 50.1 (C-2/C-6), 57.6 (NCH2), 61.9
(OCH2CH2OPh), 66.3 (C-9), 67.1 (OCH2CH2OPh), 68.3 (C-
8), 71.7 (C-4), 74.6 („CH), 84.2 (C„), 114.6 (Ar-C), 120.7
(Ar-C), 129.3 (Ar-C), 158.8 (ArC-O). Anal. Calcd for
C19H27NO3: C, 71.89; H, 8.57; N, 4.41. Found: C, 71.63;
H, 8.56: N, 4.56.
2.2.24. 4-(3-Phenoxypropoxy)-4-ethynyl-1-(2-ethoxyethyl)piperidine
(26)
Oil, 7.64 g (45.5%); Rf 0.50 (hexane:dioxane, 5:1); IR: 3290
(„CH), 3063 (Ar-H), 2100 (C„C), 1086 cm1 (COC), 755,
692 cm1; 1H NMR d 1.17 (t, 3H, H-10), 1.78–1.97 (m, 4H,H-3ax, H-5ax, H-3eq, H-5eq), 2.02 (m, 2H, OCH2CH2CH2OPh),
2.41 (s, 1H, „CH), 2.42 (bt, 2H, H-2ax, H-6ax, J= 7.8 Hz),
2.52 (t, 2H, NCH2), 2.60 (bs, 2H, H-2eq, H-6eq), 3.45 (q, 2H,
H-9), 3.49 (t, 2H, H-8), 3.72 (t, 2H, OCH2CH2CH2OPh),
4.04 (t, 2H, OCH2CH2CH2OPh), 6.86–7.28 (m, 5H, Ar-H);
13C NMR ppm 15.1 (C-10), 29.9 (OCH2CH2CH2OPh), 36.3
(C-3/C-5), 50.2 (C-2/C-6), 57.6 (NCH2), 59.4 (OCH2CH2-
CH2OPh), 64.6 (OCH2CH2CH2OPh), 66.3 (C-9), 68.3 (C-8),
71.2 (C-4), 74.1 („CH), 84.5 (C„), 114.4 (Ar-C), 120.4 (Ar-
C), 129.3 (Ar-C), 159.0 (ArC-O). Anal. Calcd for
C20H29NO3: C, 72.47; H, 8.82; N, 4.23. Found: C, 72.46; H.
8.81; N, 4.46.
2.2.25. 4-(4-Phenoxybutoxy)-4-ethynyl-1-(2-ethoxyethyl)piperidine
(27)
Oil, 10.32 g (45.5%); Rf 0.49 (hexane:dioxane, 5:1); IR: 3290
(„CH), 3062 (Ar-H), 2102 (C„C), 1086 (COC), 755,
692 cm1; 1H NMR d 1.26 (t, 3H, H-10), 1.79–2.02 (m 8H,
H-3ax, H-5ax, H-3eq, H-5eq, OCH2CH2CH2CH2OPh), 2.53
(bt, 2H, H-2ax, H-6ax, J= 10.0 Hz), 2.54 (s, 1H, „CH), 2.65
(t, 2H, NCH2), 2.73 (bs, 2H, H-2eq, H-6eq), 3.55 (q, 2H, H-
9), 3.61 (t, 2H, H-8), 3.68 (t, 2H, OCH2CH2CH2CH2OPh),
4.05 (t, 2H, OCH2CH2CH2CH2OPh), 6.94–7.36 (m, 5H, Ar-
H); 13C NMR ppm 15.1 (C-10), 26.2 (OCH2CH2CH2-
CH2OPh), 26.6 (OCH2CH2CH2CH2OPh), 36.3 (C-3/C-5),
50.2 (C-2/C-6), 57.6 (NCH2), 62.5 (OCH2CH2CH2CH2OPh),
66.3 (C-9), 67.5 (OCH2CH2CH2CH2OPh), 68.3 (C-8), 71.2
(C-4), 74.1 („H), 84.7 (C„), 114.4 (Ar-C), 120.4 (Ar-C),
129.3 (Ar-C), 159.0 (ArC-O). Anal. Calcd for C21H31NO3: C,
73.01; H, 9.04; N, 4.05. Found: C, 72.79; H, 9.12; N, 4.07.
3. Results and discussion
The chemistry required is outlined in Scheme 1. Reduction of
key starting piperidin-4-ones 1–3 to the piperidin-4-ols 4–6 was
straightforward (Yu and MES, 2002). Ethynylation of 1 and 3
to members of 7, 8 was also accomplished in a relatively facile
manner (Fomicheva et al., 1998). Etheriﬁcation of 4–6 and 7, 8
gave members of 9–14 and 19–22, respectively, with the pro-
cess being enhanced by the addition of powdered KOH to
freshly distilled DMF at ice temperatures. This was followed
by the dropwise addition of the corresponding alkoxyethyl
bromide dissolved in dry DMF. Stirring was continued at
room temperature over 70–100 h. These mild conditions gave
9–14 and 19–22 in yields ranging from 13.3% to 22.3% and
26.6–42.0%, respectively. The positive aspect of the procedure
was the easy workup which required only a simple evaporation
of solvent. Treatment of 4–6 and 7, 8 with phenoxyalkyl bro-
mides under similar conditions led to 15–18 and 23–27 in yields
of 12.8–35.0% and 13.7–45.5%, respectively. Puriﬁcation of
products was readily achieved by ﬂash chromatography over
Al2O3 using hexane:dioxane. Side reactions accompanied the
above procedures and appeared to involve interactions of the
bromides with DMF, especially with phenoxyalkyl bromides.
Multiple variations in conditions did not alter the results, with
the highest yields being as recorded above. Surprisingly, nearly
all of the products were oils.
Conﬁrmations of the structures of 9–27 were realized by
both elemental and NMR analyses. The NMR spectra for all
members of 9–27 revealed a multiplet for H-2 and H-3 ring
protons, implying that the systems were dynamic under the
conditions employed. Signals for H-4 in alkoxyalkyl ethers
Scheme 1 (i) Ethyne, KOH, NH3 (liquid); (ii) NaBH4, i-Pr: 60; (iii) KOH, R0OCH2CH2Br, DMF, RT; and (iv) KOH, PhO(CH2)nBr,
DMF, RT.
214 V.K. Yu et al.of secondary alcohols 9–14, appeared upﬁeld by 0.26–
0.35 ppm compared to that in the starting piperidin-4-ols 4–
6. It is likely that H-4 is in an axial position to a major extent
with the large alkylalkoxy group in an equatorial arrangement.
The corresponding H-4 in 17, for example, is 0.26 ppm upﬁeld
from that in 6 while 15, 16, and 18 exhibited a range of upﬁeld
shifts of 0.28–0.37 ppm compared to the corresponding signals
in 4–6. Interestingly, the 13C NMR analysis of C-4 in ethers 9–
18 derived from secondary alcohols 4–6 and ethers of eth-
ynylpiperidin-4-ole 19–27 from 7, 8 had downﬁeld shifts of
7.4–8.5 ppm and 5.6–6.2 ppm, respectively, compared to those
in 4–6 and 7, 8. However, signals for C-3 and C-5 in these sys-
tems were shifted upﬁeld by 2.9–3.1 ppm and 2.2–2.3 ppm,
respectively. Obviously the large groups at C-4 in the tar-
get molecules inﬂuence electron density around C-3 and C-5.
No substantial changes in chemical shifts were noted for C-2
and C-6 in these derivatives.
It was decided that the oils would be converted to solid
complexes with b-cyclodextrine [b-CD] for pharmacological
screening. The ability of b-CD to serve as drug carriers resides
in certain properties, namely high stability, a sufﬁciently large
diameter of the interstice, and a good tolerance of various drug
forms by organisms (Chayka et al., 1990). Our tests were per-
formed on non-pedigreed white mice and rats of both sexes
possessing a mass range of 17–23 g. The biological activity
and toxicity of the synthetic compounds were compared to
the corresponding properties of selected medicinal prepara-
tions as standards (see Tables 1–3).
The LD50 values for the test compounds had a range
of 500–1500 mg/kg as assessed following intra-peritonealintroduction to the mice. In contrast, the standards dis-
played LD50 values as follows: Tramal (175 g/kg), No-
spa (66 mg/kg), Dimedrole (144 mg/kg), Lidocaine (95 mg/
kg), Klemastine (154 mg/kg), Euphilline (240 mg/kg), and
Streptomycin (213 mg/kg) (Krylov, 2001). Other data are
included in Table 1. Consequently, the compounds pre-
pared have quite low toxicity compared to the clinically
employed standards.
Representative examples of the agents were screened for a
variety of biological activities. To assess analgesic activity,
the well known ‘‘Tail-ﬂick’’ model was utilized via a focused
infrared ray on rat tails. Observed analgesic activities for se-
lected compounds are shown in Table 1. The data revealed that
alkoxy- and phenoxyalkyl ethers 11, 14, 17, and 18 from sec-
ondary alcohols 6 did not possess useful analgesic activity.
The best results were noted with the ethynyl analogs, namely
methoxylethyl ether 21 and aromatic ethers of N-ethoxyleth-
yl-4-ethynylpiperidin-4-ols 25–27. In terms of a common anal-
gesic effect, the latter agents were 2.4–3.0 times more effective
than Tramal. The range of common analgesia action was 180–
221 min for 21 and 25–27 whereas the corresponding duration
of action for Tramal was 75 min. In addition, Tramal did not
produce a deep analgesic effect. A number of aromatic ethers
generated deep analgesic effects such as observed for 27
[160 min], 26 [135 min], and 25 [70 min]. The ethers from N-
methyl-4-ethynylpipeirdin-4-ols 19,23, and 24 were of no effect
or of modest effect for a deep analgesic result than the N-eth-
oxyethyl derivatives. Interestingly, the 4-ethoxylethyl-4-ethy-
nyl-substituted compound 20 exhibited a deep analgesic
effect of 170 min and a common analgesic effect of 240 min.
Table 1 Analgesic activity and acute toxicity of selected members of the ether-containing piperidines.
Compound Latent period (min) Duration of deep analgesia (min) Duration of common analgesia (min) LD50 (mg/kg)
11 No eﬀect >800
14 No eﬀect >800
17 30 – 45.3 (±7.9) >1500
18 5 – 33.3 (±6.7) >1500
19 No eﬀect >800
20 5 170.0 (±12.3) 240 >1500
21 5 80.0 (±17.32) 221.67 (±6.45) >800
22 5 – 66.7 (±11.21) >800
23 No eﬀect 529.3 (±13.4)
24 5 30.0 (±12.3) 135.3 (±9.8) >1500
25 5 70.0 (±6.1) 180 >800
26 5 135.3 (±12.4) 183.3 (±17.1) >800
27 5 160.0 (±41.1) 210.0 (±0.0) 580 (±68.90)
Tramal 5 – 75.0 (±9.1) 175 (±30.15)
Klemastine 154 (±12.1)
Dimedrole 144.51 (±7.98)
Lidocaine 95 (±13.1)
No-spa 66 (±12.10)
Euphillinea 240 (±17.21)
Streptomycin 213.8 (±22.61)
Euphilline is a 4:1 mixture of theophylline:1,2-ethanediamine.
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dines 21, 22, 25, and 26 did not possess useful anti-bacterial
activity (Table 2). These agents did not inhibit growth of
gram-positive (Staphylococcus aureus) and gram-negative
(Escherichia coli, Salmonella cholerae suis, and Salmonella
typhimurium) microorganisms on meat-peptone broth. How-
ever, the phenoxybutoxy-containing system 27 did exhibit
some moderate anti-bacterial action as did ethoxyethyl and
phenoxypropyl ethers 20 and 24, respectively, but less than
did Streptomycin. The absence of the ethynyl group resulted
in a poor ability to inhibit the bacteria as seen for 11, 14,
17, and 18. The small increase in length of the side chain
in 24 had a dramatic positive effect on activity as comparedto 23. In general, an overall observation regarding anti-bac-
terial ability was that the N-methyl-containing family dis-
played slightly better activity then did the N-ethoxyethyl
derivatives as viewed by data for 19, 20, and 24 versus 17,
25, and 27, respectively, with the exception of 27 against
E. coli.
Anti-spasmolitic activity (Table 3) was evaluated on iso-
lated segments of mouse intestine with an artiﬁcial spasm being
initiated by the addition of acetylcholine, histamine, and/or
calcium chloride. The data are given in Table 3. 15 ethers of
1-(2-ethoxyethyl)-4-ethynyl-4-hydroxy-piperidines 21, 22, 26,
and 27 expressed anti-spasmotic activity in the various prepa-
rations employed. Speciﬁcally, alkoxyalkyl ethers 21 and 22
Table 2 Anti-bacterial activity of the piperidine-containing ethers after 48 h of incubation in meat-peptone broth (bacteria growth in
1:1000).a
Compound Escherichia coli Salmonella cholerae suis Salmonella typhimurium Staphylococcus aureus
11 4 4 4 4
14 4 4 4 4
17 3 3 3 4
18 4 4 4 4
19 3 4 4 4
20 3 3 2 2
21 4 4 4 4
22 4 4 4 4
23 4 4 4 3
24 2 2 2 3
25 3 4 4 4
26 4 4 4 4
27 1 3 2 2
Streptomycin 0 0 0 0
Control (inoculation void of any preparation) 4 4 4 4
a Maximum turbidity related to maximum growth of microorganisms = 4. Absence of growth of microorganisms, maximum medium
transparency = 0.
216 V.K. Yu et al.inhibited the acetylcholine-induced spasm while ethoxyethyl
ether 22 also completely blocked the histamine-induced spasm
in mouse intestine. The phenoxy-substituted ether 27 was very
inhibitory to a calcium chloride-spasm. Ethers 11 and 14 void
of an ethynl group were not effective. Results with the syn-
thetic compounds were compared to the ﬁve standard prepara-
tions as outlined in Table 3.
To assess anti-allergic ability of the compounds, mem-
brane-stable activity was studied via observance of indirect
degranulation of fat cells [IDFC] (Methodical Instructions
on Evaluation of Allergic Properties of Pharmacological
Drugs, 1988). The biological activity was compared with that
of Dimedrole and Klemastine [Histamine-1 blocking andTable 3 Anti-spasmotic activity of selected piperidine-con-
taining ethers [change in length (mm) of an isolated piece of
intestine after stimulation when attached to isolated organs]
(Kuzdenbayeva et al., 2000).
Compound Clonus of
intestinea
Clonus of
intestineb
Clonus of
intestinec
Clonus of
intestined
11 0 4.0 4.0 NA
14 0 4.0 4.0 NA
21 2 0.0 2.0 NA
22 0 0.0 0.0 NA
26 0 1.0 2.0 NA
27 0 1.0 NA 0.0
No-spa 0 0.0 0.0 0.0
Euphilline 0 0.0 0.0 0.0
Acetylcholine 5.0
Histamine 4.3
CaCl2 2.5 ± 0.1
NA= not available.
a After the introduction of a preparation.
b In the presence of a preparation and acetyl choline.
c In the presence of a preparation and histamine.
d In the presence of a preparation and with a 10% solution of
CaCl2.anti-allergic action, respectively]. The pharmacological testing
using methoxyethyl, ethoxyethyl, and phenoxypropyl ethers
21, 22, and 26, respectively, derived from 1-(2-ethoxyethyl)-
4-ethynyl-4-hydroxy- piperidines 8 was accomplished using
the stable membrane model of degranulated fat cells from
rats. Activity was noted with 22 which displayed ability com-
parable to that of the standard Dimedrole. Surprisingly, the
phenoxypropyl derivative 26 surpassed Dimedrole in anti-
allergic activity and in toxicity with respect to the model of
degranulation of fat cells of the rat. However, the activity
of 26 was less than that of Klemastine as seen in Table 4 con-
taining data of some selected compounds. The smaller the
value for the index of degranulation of fat cells (IDFC) the
greater the anti-allergic induced activity by the agent. Inter-
estingly, the systems 11 and 14 void of the ethynl group
did not exhibit useful anti-allergic activity. It is apparent that
very small changes in the structures induce sharp alterations
in properties of this group of compounds. These observed
activities prompt additional efforts to explore this novel fam-
ily of heterocycles with potentially useful and wide ranging
medicinal properties.
Since piperidines and many derivatives have been investi-
gated with respect to conformational analysis, a few brief
comments are in order for the derivatives discussed herein.
In conformationally locked systems, 13C NMR analysis has
clear demonstrated that an N-methyl bond is essentially
99% equatorial (Crowley et al., 1977; Appleton et al., 1977;
Delpuech, 1977). Consequently, it is reasonable that
the piperidine systems in our work are also effectively locked
systems with all large groups bonded to the ring in equatorial
arrangements. It is also well known (Hennion and
O’Shea, 1958) in cyclohexyl systems that the addition of so-
dium acetylide to 4-t-butylcyclohexanone results in the ethyne
group in an axial position and the hydroxyl group in the
equatorial position. The linear ethyne group apparently
offers only small 3,5-interactions with axial C–H bonds.
Thus, the ethynyl functions in the molecules prepared in our
study are most likely in axial positions in a locked six-
membered ring.
Table 4 Activity of piperidine-containing ethers and standards on stable membrane preparations – an examination of anti-allergic
activity.
Compound Index of degranulation of fat cells
after the introduction of 0.03 ml
of a 0.01% acetylcholine
Index of degranulation of fat
cells after the introduction of 0.03 ml
of a 0.01% histimime
11 NA 2.2 (±0.009)
14 NA 2.0 (±0.011)
21 2.0 (±0.001) 1.9 (±0.0005)
22 1.7 (±0.001) 1.5 (±0.001)
26 NA 1.0 (±0.01)
Histamine NA 3.0 (±0)
Acetylcholine 3.0 (±0) NA
Dimedrole NA 1.374 (±0.01)
Klemastine NA 0.14 (±0.005)
Index of degranulation relates to degranulation of fat cells which is a quantitative comparative measure of the expression of granules ejected by
standard allergic agents (histamine or acetylcholine) from fall cells (Methodical Instructions on Evaluation of Allergic Properties of Phar-
macological Drugs, 1988).
NA= not available.
Synthesis and properties of novel alkoxy- and phenoxyalkyl ethers 2174. Conclusions
A series of secondary- and tertiary-substituted piperidin-4-ols
containing ethoxy groups have been prepared and exhibit wide
ranging biological properties which include activities such as
analgesic, anti-bacterial, anti-spasmotic, and anti-allergic.
High LD50 values clearly indicate the compounds to be of
low toxicity, an important quality for future evaluations. The
presence of an ethynyl group at C-4 in N-ether-substituted
piperidine markedly enhanced the analgesic activity of several
agents. The presence of alkoxy and phenoxy ether linking
groups at C-4 of the piperidines also contributed to the biolog-
ical action of the substituted piperidines.Acknowledgements
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